AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00740688 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Logan Basic Apex Contact
Description: A Logan Basic Apex Contact, which is a contact that is placed on the anterior surface of the sacrotuberous ligament with a light force directed posterior with varying degrees of laterality.
Study NCT00740688 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Logan Basic apex contact
Description: light force contact applied to the inferior surface of the sacrotuberous ligament, directed straight superiorly.
Study NCT04104893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is a programmed death receptor-1 (PD 1)-blocking antibody. Pembrolizumab is a humanized monoclonal IgG4 kappa antibody with an approximate molecular weight of 149 kDa. Pembrolizumab is produced in recombinant Chinese hamster ovary (CHO) cells.
Study NCT00669591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bavituximab
Description: Weekly bavituximab infusion of 3 mg/kg combined with up to six 28-day cycles of docetaxel chemotherapy. After treatment phase, weekly bavituximab maintenance is continued until disease progression.
Study NCT02531919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Bicarbonate
Description: Given PO
Study NCT01064986 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Endotoxin, Lipopolysaccharide, LPS
Description: Clinical Center Reference Endotoxin, lot 2, sterile saline, 1 ng/kg, bolus IV administration (\~5 minutes)
Study NCT01064986 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Endotoxin, Lipopolysaccharide, LPS /Epinephrine
Description: Clinical Center Reference Endotoxin, lot 2, sterile saline, 1 ng/kg, continuous IV administration (Hydrocortisone 3mcg/kg/min)
Study NCT01064986 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline vehicle (placebo)
Study NCT01618617 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High dose Multistrain probiotic, 100 billion cfu/day
Description: 100 billion cfu live bacteria (60 billion cfu bifidobacterium cultures and 40 billion lactobacillus cultures).
Study NCT01064986 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone
Description: Hydrocortisone
Study NCT01618617 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low dose Multistrain probiotic, 15 billion cfu/day
Description: 15 billion cfu live bacteria (9 billion cfu bifidobacterium cultures and 6 billion lactobacillus cultures).
Study NCT02417285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: 1000 mg administered IV on Days 2, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2 though 8.
Study NCT02417285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-122
Description: CC-122 1mg, 2mg, 3mg, 4mg or 5mg administered orally once daily on a 5/7-day schedule in each 28-day cycle. In addition, subjects will be enrolled on the CC-122 formulated capsule (F6) and evaluated for safety and tolerability in combination with GA101 (Obinituzumab) in a separate cohort. The CC-122 dose will be escalated until the MTD is established on the CC-122 formulated capsule (F6) in combination with GA101 (Obinituzumab).
Study NCT01453946 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Entocort
Description: Entocort capsules, taken orally, 6 mg daily.
Study NCT02469597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide
Description: 1 mg/kg intravenous or oral (will give oral unless patient has peripheral IV access in place), maximum dose 10mg (1ml), x 1 dose
Study NCT02469597 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.1ml/kg intravenous or oral (Normal Saline) (will give oral unless patient has peripheral IV access in place), maximum dose 1ml, x 1 dose
Study NCT01110486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-348
Description: An oral dose of ABT-348, once daily on Day 1, Day 8, and Day 15 of each 28 day cycle.
Study NCT01110486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-348 and carboplatin
Description: An oral dose of ABT-348 will begin in Cycle 2on Day 1 and Day 8; and an IV dose of carboplatin (AUC 5.0) on Day 1 of each 21-day cycle.
Study NCT01110486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-348 and docetaxel
Description: ABT-348 dosing will begin in Cycle 2. An oral dose of ABT-348 on Day 1 and Day 8; and an IV dose of docetaxel (75 mg/m2) on Day 1 of each 21-day cycle.
Study NCT01178372 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactulose
Description: will receive 30-60 ml of lactulose in 2 or 3 divided doses so that patient passed 2-3 semisoft stools per day
Study NCT01178372 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Probiotics(VSL#3)
Description: will receive VSL#3 (110 billion CFU)three times a day
Study NCT01110486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-348
Description: An oral dose of ABT-348, twice daily on Day 1, Day 8, and Day 15 of each 28 day cycle
Study NCT01110486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-348
Description: An IV administration of ABT-348 two hour infusion on Day 1, Day 8 and Day 15 of each 28 day cycle.
Study NCT04420065 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Preferential left ventricular pacing
Description: Activation of an algorithm attempting to provide preferential left ventricular pacing in an anticipatory manner, thus potentially preventing iatrogenic, pacing-related, right ventricular dysfunction, and improving coupling and outcomes in dyssynchronous heart failure patients
Study NCT04420065 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biventricular pacing
Description: Standard biventricular pacing, with V-V delay programmed based on stroke volume maximization, and A-V delay delegated to the device
Study NCT02807194 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: spinal anesthesia
Study NCT02807194 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: general anesthesia
Study NCT02807194 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lumbar disc herniation
Study NCT00639808 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 5% dextrose in water
Description: 60 ml IV infusion over 30 minutes
Study NCT00639808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TZP-101
Description: 1 infusion: IV 2ml/min for 30 minutes for 1 day of either 160, 320 or 600 micrograms/kg
Study NCT02299544 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BlueWind Medical system
Description: The BlueWind Medical System is intended for the treatment of patients with overactive bladder (OAB) including urinary urgency frequency and urge incontinence.
Study NCT01873196 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Receive extra oil
Study NCT01873196 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Receives behavior changed messages on CSB package
Study NCT01911884 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: evaluate quality of life of surgical and non surgical vaginal aplasia
Description: protocol designed to evaluate quality of life of surgical and non surgical vaginal aplasia
Study NCT04652349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP1910
Description: Take it once daily for 8 weeks orally.
Study NCT04652349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP1903
Description: Take it once daily for 8 weeks orally.
Study NCT04652349 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HGP1909
Description: Take it once daily for 8 weeks orally.
Study NCT04652349 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HGP1911
Description: Take it once daily for 8 weeks orally.
Study NCT05839002 — intervention group
Intervention type: PROCEDURE
Intervention: nCRT
Description: ESCC patients that recieved surgery and nCRT.
Study NCT01197495 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hyaluronic acid gel
Description: Dosage per Investigator's discretion to obtain lip treatment gel; 1 touch-up treatment is allowed 14 to 30 days after initial treatment. Repeat treatment occurs at month 12. Subjects in the control group start with treatment at month 3. Maximum total volume per subject is 4.8 mL for initial and touch-up treatment combined.
Study NCT03113799 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Smart External Drain - SED
Description: Subject will be treated on Day 2 with the SED. ICP and CSF volumes will be recorded at prespecified intervals while subject is stationary and while subject is engaged in protocol-driven directed movements.
Study NCT03419377 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard care and sexological counseling
Description: 6-8 sexological consultants in a period of six months
Study NCT05082350 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: black garlic
Description: Daily consumption of 4 cloves of black garlic, not cooked, during 12 weeks
Study NCT03430505 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bilevel
Description: Basal respiratory mechanics in spontaneous breathing will be analyzed by optoeletronic plethismography (OEP), followed by bronchial provocation with hypertonic saline solution 4.5%, another 45-second OEP uptake, IPAP 12 and EPAP 8 bilevel applied for 10 minutes, and a new uptake. All abstractions are preceded by a forced and slow spirometry maneuver. The entire procedure takes 1 hour.
Study NCT03430505 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albuterol
Description: Basal respiratory mechanics in spontaneous breathing will be analyzed by optoeletronic plethismography (OEP), followed by bronchial provocation with hypertonic saline solution 4.5%, another 45-second OEP uptake, 400 micrograms inhaled Albuterol, and a new uptake. All abstractions are preceded by a forced and slow spirometry maneuver. The entire procedure takes 1 hour.
Study NCT03745183 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Senna alata leaf decoction
Description: Preparation of the akapulko decoction~1. Remove the leaflets from the rachis of a mature leaf.~2. Wash the mature leaflets thoroughly to remove dust, dirt and debris.~3. In the clay, enamel, or stainless steel pot, place one glassful of closely packed chopped leaves (350 ml glass) and add 2 glasses (around 700ml) of clean water . Use the same glass for measuring the leaves and water.~4. Cook the leaves and bring to a rolling boil.~5. When the fluid is reduced to half, remove the decoction from the fire and cool slightly.~6. Strain the mixture using cheesecloth and press the cut leaves in the strainer to make sure to get as much liquid out of them.~7. Place the liquid in a clean container (bottle/jar with cover). Label the container clearly as Akapulko.
Study NCT04393688 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Combination Product: Tri-wire Peripheral Balloon Dilatation Catheter
Description: Procedure:~Percutaneous Transluminal Angiography, Percutaneous transluminal angioplasty (PTA) is a procedure that can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a balloon at the end of it. When the tube is in place, it inflates to open the blood vessel, or artery, so that normal blood flow is restored.
Study NCT04393688 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Combination Product: Tri-wire Peripheral Balloon Dilatation Catheter
Description: Procedure:~Percutaneous Transluminal Angiography, Percutaneous transluminal angioplasty (PTA) is a procedure that can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a balloon at the end of it. When the tube is in place, it inflates to open the blood vessel, or artery, so that normal blood flow is restored.
Study NCT02921711 — intervention group
Intervention type: DEVICE
Intervention: LVIS®
Description: Low-profile Visualized Intraluminal Support device
Study NCT02380612 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ReCell Treatment
Study NCT02380612 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Skin Graft
Study NCT02713607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: Given doxycycline to acne subjects
Study NCT04545177 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NICO Myriad and Tissue Preservation System (TPS)
Description: Tumor tissue will be obtained by the NICO Myriad and Tissue Preservation System (TPS) via an automated, standardized methodology
Study NCT02335047 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Impaired passivity test
Description: Description of the test: the subject lies in the supine position on an exercise mat with his/her feet together. The subject is told to let his/her arms rest loosely by his/her side (as if they were ropes) and to keep the head aligned with the back. The examiner pulls the subject into the sitting position by pulling on the subject's wrists, with passive flexion of the trunk until the hip joint is fully flexed..
Study NCT01118104 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Vocational pulmonary rehabilitation
Description: Multidisciplinary pulmonary rehabilitation with emphasis on vocational issues
Study NCT02125903 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Regional Anesthesia performed with 0.375% Ropivacaine 15ml (56,25mg)
Study NCT00896363 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GSK163090 1 mg
Description: Developed for the treatment of Major Depressive Disorder
Study NCT00896363 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GSK163090 Placebo
Description: Developed for the treatment of Major Depressive Disorder
Study NCT00896363 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GSK163090 3 mg
Description: Developed for the treatment of Major Depressive Disorder
Study NCT02607241 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: OCT-guided BRS implantation
Description: Implantation of a BRS using OCT to measure vessel size, choose BRS size and length and assess implantation results and the need of further postdilations
Study NCT02607241 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FFR-guided DCB-only PCI
Description: PCI performed under FFR guidance using following algorithm: (1) predilation followed by angiographic assessment of residual stenosis and dissections; (2) evaluate suitability for DCB-only, which is deemed feasible if the FFR > 0.8, residual diameter stenosis \< 40% and no flow-limiting dissections are observed; (3) DCB dilation and (4) assessment of final results using FFR and QCA measurements. Provisional stenting is allowed only if the final PCI results are not acceptable (flow-limiting dissection, residual stenosis > 40% or FFR \< 0.8).
Study NCT03633630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amla
Description: Capsules of 500 mg two times per day before breakfast and dinner a total dose of 1000 mg per day. During 90 days
Study NCT03633630 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules of 500 mg two times per day before breakfast and dinner a total dose of 1000 mg per day. During 90 days
Study NCT02759107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC
Study NCT02759107 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study NCT02759107 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dulaglutide
Description: Administered SC
Study NCT03095027 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: FID122819 contact lenses
Description: Investigational spherical silicone hydrogel contact lenses for daily disposable wear
Study NCT03095027 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Stenfilcon A contact lenses
Description: Commercially available spherical silicone hydrogel contact lenses for daily disposable wear
Study NCT03041675 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser Acupuncture group
Description: 47 participants receive 10 seconds of Laser Acupuncture(808nM/300mW) on acupoints RN6, RN4, and RN12. The whole duration of treatment is 3 times a week, for 8 weeks.
Study NCT03041675 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Laser Acupuncture group
Description: The investigators apply the Laser Acupuncture pen (without pressing the Laser button) on other 47 participants' acupoints RN6, RN4, and RN12. The whole duration of treatment is 3 times a week, for 8 weeks.
Study NCT00062023 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylsalicylic acid (Aspirin)
Description: Patients receive oral aspirin once daily for 12 months.
Study NCT00062023 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulindac
Description: Patients receive oral sulindac twice daily for 12 months.
Study NCT00062023 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ursodiol
Description: Patients receive oral ursodiol three times daily for 12 months.
Study NCT00062023 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sulindac Placebo
Description: Oral sulindac placebo twice daily.
Study NCT04165655 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Keep Achieving (KA)
Description: The 10-week group based activity programme will consist of 10 sessions each lasting 50 minutes.
Study NCT02596373 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mitoxantrone Hydrochloride Liposome Injection
Study NCT02596373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone Hydrochloride Liposome Injection
Study NCT02830347 — intervention group
Intervention type: DRUG
Intervention: Amoxicillin
Description: Extraction
Study NCT02830347 — intervention group
Intervention type: PROCEDURE
Intervention: Extraction
Description: Extraction of third molars
Study NCT02429713 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Short-duration tourniquet
Description: Short-duration tourniquet group:inflate the tourniquet immediately before cement application and deflated after its hardening
Study NCT02429713 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Long-duration tourniquet
Description: Long-duration tourniquet group: inflate the tourniquet immediately before incision and deflated after the hardening of the cement
Study NCT00539513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine
Description: 3000 mg by mouth PO (1200 mg AM, 1800 mg PM), 12 weeks
Study NCT00539513 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo, 2 capsules PO AM, 3 capsules PO PM, 12 weeks
Study NCT06408675 — intervention group
Intervention type: OTHER
Intervention: Visual Analog Scale (VAS), QOL (36-Item Short Form Survey (SF-36)), and Neck Disability Index (NDI) were used to assess pain, overall quality of life, functional disability respectively.
Description: Visual Analog Scale (VAS), QOL (36-Item Short Form Survey (SF-36)), and Neck Disability Index (NDI) were used to assess pain, overall quality of life, functional disability respectively.
Study NCT06167005 — intervention group
Intervention type: PROCEDURE
Intervention: Primary bariatric-metabolic surgery
Description: Primary bariatric-metabolic surgery
Study NCT03166228 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline 0.9% Infusion Solution Bag
Description: 0.9% saline as distension medium as long as diathermy is not in use
Study NCT03166228 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 1.5% Glycine only
Description: 1.5% Glycine alone during hysteroscopy as long as diathermy is in use
Study NCT03431623 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CKD-11101(Darbepoetin alfa)
Study NCT03431623 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: NESP(Darbepoetin alfa)
Study NCT00175838 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxyurea
Description: Hydroxyurea (or hydroxycarbamide) is an antineoplastic drug commonly used to treat haematological malignancies.
Study NCT00175838 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Aspirin is an anti-aggregating agent, and has been shown to reduce/alleviate minor ischaemic symptoms.
Study NCT02149628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol
Study NCT02149628 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desflurane
Study NCT03742687 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Heterogeneously Hypofractionated Radiotherapy
Description: A heterogeneous hypofractionated schedule for the treatment of high-risk locally advanced NSCLC patients in which the central idea is to decrease dose to normal tissue by ascribing a heterogeneous dose to the PTV. The dose to the periphery of the PTV as well as to the majority of lymph node targets is decreased compared to a standard treatment. The gross volume of the primary tumour and bulky lymph nodes receive mean doses of up to 66 Gy in 24 fractions, and thus receive a hypofractionated higher biological effective dose than standard 66 Gy in 33 fractions.
Study NCT01202643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: One infusion of G-CSF 300 units administered by intrauterine infusion
Study NCT01202643 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: One intrauterine saline infusions of 1 cc